ARTL, operating in its industry, demonstrates strong financial ratios with low debt (2.87%) and adequate liquidity (22.56%), but insufficient data on income sources and primary business activities in cannabinoid therapeutics raise significant Shariah compliance concerns. The company fails business activity screening due to involvement in potentially haram substances, leading to non-compliance across major indices. While financial metrics support compliance, qualitative business review dominates the assessment. Purification is not required based on available data, but investors should monitor for updates. Overall, ARTL is not recommended for Shariah-compliant portfolios without further scholarly review.